NetraMark Holdings Inc. announced that it has entered into a Master Service Agreement with a large public listed biopharmaceutical company. The agreement paves the way for collaboration, whereby NetraMark will employ its unique Generative AI technology platform to analyze clinical trial data from select candidate medicines of the biopharmaceutical company. the primary objective being to discover specific subpopulations and shed light on unique patient enrichment therapies related to drug and placebo responses.

The agreement follows an extensive and rigorous evaluation of NetraMark by the biopharmaceutical company, including a comprehensive vendor qualification audit, ensuring adherence to the highest standards of Good Clinical Practice (GCP).